118 related articles for article (PubMed ID: 18927298)
1. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.
Kondo E; Maecker B; Weihrauch MR; Wickenhauser C; Zeng W; Nadler LM; Schultze JL; von Bergwelt-Baildon MS
Clin Cancer Res; 2008 Oct; 14(20):6574-9. PubMed ID: 18927298
[TBL] [Abstract][Full Text] [Related]
2. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.
Kondo E; Maecker B; Draube A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; Schultze JL; von Bergwelt-Baildon MS
Int J Cancer; 2009 Nov; 125(10):2474-8. PubMed ID: 19681121
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.
Wang M; Sun L; Qian J; Han X; Zhang L; Lin P; Cai Z; Yi Q
Leukemia; 2009 Jul; 23(7):1320-8. PubMed ID: 19225534
[TBL] [Abstract][Full Text] [Related]
4. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
5. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules.
Sadovnikova E; Jopling LA; Soo KS; Stauss HJ
Eur J Immunol; 1998 Jan; 28(1):193-200. PubMed ID: 9485199
[TBL] [Abstract][Full Text] [Related]
6. Ring finger protein 43 as a new target for cancer immunotherapy.
Uchida N; Tsunoda T; Wada S; Furukawa Y; Nakamura Y; Tahara H
Clin Cancer Res; 2004 Dec; 10(24):8577-86. PubMed ID: 15623641
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.
Maecker B; von Bergwelt-Baildon MS; Sherr DH; Nadler LM; Schultze JL
Int J Cancer; 2005 Jun; 115(2):333-6. PubMed ID: 15688394
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
9. Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses.
Tajima K; Demachi A; Ito Y; Nishida K; Akatsuka Y; Tsujimura K; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Tissue Antigens; 2004 Dec; 64(6):650-9. PubMed ID: 15546337
[TBL] [Abstract][Full Text] [Related]
10. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
[TBL] [Abstract][Full Text] [Related]
11. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
12. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
13. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
14. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
17. Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.
de Rijke B; Fredrix H; Zoetbrood A; Scherpen F; Witteveen H; de Witte T; van de Wiel-Van Kemenade E; Dolstra H
Blood; 2003 Oct; 102(8):2885-91. PubMed ID: 12842998
[TBL] [Abstract][Full Text] [Related]
18. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
19. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
Linnebacher M; Gebert J; Rudy W; Woerner S; Yuan YP; Bork P; von Knebel Doeberitz M
Int J Cancer; 2001 Jul; 93(1):6-11. PubMed ID: 11391614
[TBL] [Abstract][Full Text] [Related]
20. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
